HNN3.0

Project cooperationUpdated on 21 April 2026

Antion Biosciences: Gene Engineering Solutions

Scientist at Antion Biosciences

Plan-Les-Ouates, Switzerland

About

Antion's gene engineering technology is available for collaborative projects seeking to achieve ambitious goals. Antion's proprietary gene engineering technology offers key highlights:

A gene silencing platform with exceptional multiplexing capabilities.

Ability to simultaneously modify multiple genetic targets within a single cell, and co-expressing molecules of interest (ex: a CAR).

Precise tuning of target gene expression levels, highly versatile and applicable in a variety of settings and cell types, autologous or allogeneic therapy, cell and gene therapy, applicable for ex-vivo and in-vivo delivery methods.

Presents a highly favorable safety profile compared to gene editing approaches.

Topic

  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic non-communicable diseases: implementation research maximising collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways
  • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalised approaches
  • DESTINATION 4: HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices
  • DESTINATION 5: HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)
  • DESTINATION 6: HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies

Type

  • Partner seeks Consortium/Coordinator

Organisation

Antion Biosciences

Company (SME)

Geneva, Switzerland

Similar opportunities